News & Updates | Alliance Healthcare UK

Updates

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Fasturtec® 7.5 mg. 1.5 mg/ml

Sanofi has informed us of an Out Of Specification (OOS) result which was detected for Rasburicase enzyme activity according to a specific method and specifications for US market, at 12 months stability time point. Sanofi is recalling Fasturtec® 7.5 mg (Rasburicase) Solution for IV infusion - 7.5 mg/5 ml (Injectable powder in vial packaged with 5 ml solvent in ampoule), batch number A9306 as a precautionary measure.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
3338928	Fasturtec® 7.5 mg. 1.5 mg/ml powder and solvent for concentrate for solution for infusion	Sanofi	A9306

For medical information enquiries please contact uk-medicalinformation@sanofi.com Med Info Phone :0800 035 25 25.

For stock control enquiries please contact GB-CustomerServices@sanofi.com Phone number: 0800 854 430

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on SmofKabiven extra Nitrogen Electrolyte Free

Fresenius Kabi Ltd & Calea UK Ltd has informed us of an error on the bag labels for SmofKabiven extra nitrogen electrolyte free, emulsion for infusion PL 08828/0269. A sentence has been inadvertently included stating "with electrolytes" on an electrolyte free product. The outer cartons and leaflets have been checked and these are all in compliance. The bag label should state "1. Amino acid solution.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
Alliance do not stock	SmofKabiven extra Nitrogen Electrolyte Free	Fresenius Kabi Ltd & Calea UK Ltd	10NI3300 10PB8836

Alliance healthcare do not stock this product and as this is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Medical.Information-UK@fresenius-kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Phosphates Solution For Infusion 500ml

Huddersfield Pharmacy Specials (HPS) is recalling the above batches of phosphates solution for infusion due to observation of precipitation in batch 500609X. The decision to recall all other batches has been made as a precautionary measure.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
Alliance do not stock	Phosphates Solution For Infusion 500ml	Huddersfield Pharmacy Specials (HPS)	Please follow the above link

Alliance Healthcare do not stock this line therefore we will not be accepting customer returns.

For stock control queries please contact: HPS Customer Services, 01484 355388.

For any medical information enquires please contact: Dr Burrinder Grewal, 01484 355230.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Clexane 4,000 Iu (40mg) /0.4ml Syringes

Pharmaram Ltd has informed us that the below batch of Clexane 4,000IU (40mg)/0.4ml syringes has an error on the labelling affixed to the plastic blister packaging encasing the syringe. The label incorrectly states "Clexane 6,000IU (60mg)/0.6ml Syringes", when it should have stated "Clexane 4,000IU (40mg)/0.4ml Syringes". The outer carton states the correct strength; the batch number and expiry dates are also correct and match the details on the labelling.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
8129165	PI CLEXANE PFS 40MG	PHARMARAM LTD	CCL67G/D3

For stock control queries please contact:Pharmaram Ltd Austin Chambers Email: austin@dixpharm.com Tel: +44 (0) 1530 410920 Mob: +44 (0) 7944 664400

For any medical information enquires please contact: Pharmaram Ltd Email: quality@dixpharm.com Tel: +44 (0) 1530 410920

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

Crescent Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the below batches is missing important safety relevant text changes.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch

4091625SYRENIRING 0.12MG/0.015MG 24 HRCRESCENT PHARMA LTDLF18276AA
LF18894AA

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Crescent Pharma Ltd. Medical Information Department on +00351 214643225, via email on tiago.barca@pharsolution.com or +44 (0) 1256 772740.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Digoxin Tab 250mcg

Accord-UK Ltd has informed us of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D code, the status of packs may report as ‘EXPORT.' Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Livery	Affected Batch
1063015	Digoxin Tab 250mcg	Accord UK Ltd	XDG396

For stock control enquiries please contact Accord-UK Ltd Customer Services Team on 0800 373573.

For medical information enquiries please contact Accord-UK Ltd Medical Information Department on 01271 385257.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Abstral Tab 200mcg (Schedule 2 CD)

Kyowa Kirin Limited is recalling the above batch as a precautionary measure, due to the reports of double tablets in a single blister pocket. This was identified during reference sample inspection and there is a potential low risk of accidental double dosage.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
3460375	ABSTRAL TAB 200MCG (SCHEDULE 2 CD)	KYOWA KIRIN	608777302

As this product is a Schedule 2 Controlled Drug. Please ensure that these returns are sent back with the Alliance Healthcare driver, who will have a ‘Specialist Product Recall Book' with them on Thursday 30th and Friday 31st July for completion and product uplift AM ONLY. If you have recalled products to return, please have this prepared in a bag for the driver to uplift. Due to Covid 19, the driver will complete the form on your behalf. They will ask for the quantity of stock you have to return and the name of the pharmacist. The driver will give you a copy of the completed form for your records. Please use our Returns Portal from Saturday 1st August for any additional returns related to this recall or alternatively call Customer Service for authorisation to return

Further Information

For Stock control enquiries please contact: Stuart Hay, Commercial Director Telephone: +44 (0) 1896 664045 Mobile: +44 (0) 7968 983286 E-mail: Stuart.Hay@kyowakirin.com For Medical information enquiries please contact:

Medical Information Direct Line: + 44 (0)1896 664 000 E-mail: medinfo@kyowakirin.com For Quality information please contact: Martin Smith (Responsible Person)

Telephone: +44 7904671807 E-mail: Martin.Smith@kyowakirin.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Irinotecan Vial 20mg/Ml

Accord Healthcare Limited is recalling the above batch as a precautionary measure, due to the observation of precipitation in the solution in the same batch marketed in another country (Malta). No complaints or adverse reaction reports have been received by the company to date for the UK product.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Livery	Affected Batch
1216860	Irinotecan Vial 20mg/Ml	Accord Healthcare	X21343
1123835	Irinotecan Vial 20mg/Ml	Accord Healthcare	X21343

For more information or medical information queries, please contact:Medinfo-BST Tel: 01271 385257 E-mail: medinfo@accord-healthcare.com

For stock control queries, please contact: Accord-UK Ltd Customer Services Team Tel: 0800 373573 E-mail: customerservices@accord-healthcare.com Fax: 01271 346106

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Ecalta 100mg Powder For Concentrate For Solution For Infusion

Pfizer Limited has informed us that the packs for the above batches have not been packaged with the current version of the Patient Information Leaflet (PIL) containing updated storage instructions of the infusion solution in section 5.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
3523594	ECALTA 100MG PWD FOR CONC (IV)	PFIZER LTD	DN 6937 DX 1158

Further Information

For suspected adverse reaction and/or medical information queries, please contact: Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS Telephone: 01304 616 161

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

This is a caution in use only we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Ibuprofen 200mg And 400mg Tablets

Aspar Pharmaceuticals Limited has informed us that the Patient Information Leaflets (PILs) within the ibuprofen packs below are missing some information identified from post-marketing experience that should be documented in Section 3 (How To Take The Tablets) and Section 4 (Possible Side Effects) of the PIL.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Livery	Affected Batch
6835151	IBUPROFEN TAB 200MG	ASPAR PHARMACEUTICALS	Please refer to link above
6835169	IBUPROFEN TAB 200MG	ASPAR PHARMACEUTICALS	Please refer to link above
1000132	IBUPROFEN TAB 200MG	ASPAR PHARMACEUTICALS	Please refer to link above
1038892	IBUPROFEN TAB 200MG	ASPAR PHARMACEUTICALS	Please refer to link above
1077601	IBUPROFEN TAB 200MG	ASPAR PHARMACEUTICALS	Please refer to link above
1187509	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above
6835177	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above
6835185	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above
1058262	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above
1130509	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above
1130491	IBUPROFEN TAB 400MG	ASPAR PHARMACEUTICALS	Please refer to link above

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

This is a caution in use only and therefore we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.